VIENNA (MedPage Today) -- Treatment with gefitinib, a targeted EGFR inhibitor, failed to improve survival in advanced esophageal cancer but did slow disease progression, according to a study reported here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com
Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2012/09/gefitinib-offers-modest-results-in.html
No comments:
Post a Comment